Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Estimates of the Undetected Rate among the SARS-CoV-2 Infected using Testing Data from Iceland

James H. Stock, Karl M. Aspelund, Michael Droste, Christopher D. Walker
doi: https://doi.org/10.1101/2020.04.06.20055582
James H. Stock
aDepartment of Economics, Harvard University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: james_stock@harvard.edu
Karl M. Aspelund
bDepartment of Economics, MIT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Droste
aDepartment of Economics, Harvard University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher D. Walker
aDepartment of Economics, Harvard University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Testing for SARS-CoV-2 in the United States is currently targeted to individuals whose symptoms and/or jobs place them at a high presumed risk of infection. An open question is, what is the share of infections that are undetected under current testing guidelines? To answer this question, we turn to COVID-19 testing data from Iceland. The criteria for testing within the Icelandic medical system, processed by the National University Hospital of Iceland (NUHI), have also been targeted at high-risk individuals, but additionally most Icelanders qualify for voluntary testing through the biopharmaceutical company deCODE genetics. We use results from Iceland’s two testing programs to estimate the share of infections that are undetected under standard (NUHI) testing guidelines. Because of complications in the deCODE testing regime, it is not possible to estimate a single value for this this undetected rate; however, a range can be estimated. Our primary estimates for the fraction of infections that are undetected range from 88.7% to 93.6%.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

At the moment we have no external support for this project (which is in process). This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. 1122374.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data are publicly available. We use counts of tests and confirmed COVID-19 infections from the Icelandic Health Directorate's COVID-19 information website. We also use counts of cases reporting flu-like symptoms from the influenza website of the country's Health Directorate. We use quarantine numbers from the Department of Civil Defense's announcement page.

https://www.landlaeknir.is/servlet/file/store93/item32967/influensulik.einkenni.uppfaersla.a.vef.okt2017.AG.xls_%C3%A1n%20myndar%20og%20aldursdreifingu.xls

https://www.covid.is/data

https://www.almannavarnir.is/utgefid-efni/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 11, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Estimates of the Undetected Rate among the SARS-CoV-2 Infected using Testing Data from Iceland
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Estimates of the Undetected Rate among the SARS-CoV-2 Infected using Testing Data from Iceland
James H. Stock, Karl M. Aspelund, Michael Droste, Christopher D. Walker
medRxiv 2020.04.06.20055582; doi: https://doi.org/10.1101/2020.04.06.20055582
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Estimates of the Undetected Rate among the SARS-CoV-2 Infected using Testing Data from Iceland
James H. Stock, Karl M. Aspelund, Michael Droste, Christopher D. Walker
medRxiv 2020.04.06.20055582; doi: https://doi.org/10.1101/2020.04.06.20055582

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (171)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8797)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1867)
  • Geriatric Medicine (179)
  • Health Economics (389)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (493)
  • Hematology (207)
  • HIV/AIDS (396)
  • Infectious Diseases (except HIV/AIDS) (10580)
  • Intensive Care and Critical Care Medicine (565)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1763)
  • Nursing (104)
  • Nutrition (267)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (966)
  • Ophthalmology (284)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (265)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1846)
  • Public and Global Health (3992)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (536)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)